Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics宣布了一项新的美国专利，该专利涵盖了左旋西门丹在心力衰竭肺动脉高压中的使用，同时保持射血分数，新专利为2040年12月提供保护
Tenax Therapeutics Announces New US Patent Covering The Use Of Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction, The New Patent Provides Protections Through December 2040
Tenax Therapeutics宣布了一项新的美国专利，该专利涵盖了左旋西门丹在心力衰竭肺动脉高压中的使用，同时保持射血分数，新专利为2040年12月提供保护
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。